Aducanumab is designed to target the underlying damage to the brain
- Works by targeting the hallmark tangle of proteins in Alzheimer's patients
- Study showed those who took drug had reduced build up after a year
- Experts hailed the findings as 'game-changing' and 'unprecedented'
A revolutionary drug that could stop people from ever developing Alzheimer’s disease has been unveiled by scientists.
Trials have produced ‘unprecedented’ results and the medicine has been hailed as a potential game-changer in the fight against the cruel disease.
In future, healthy pensioners could be prescribed the drug to ward off dementia, in much the same way as statins are given today to those at risk of heart attacks.
One British expert described the drug, which is about to be tested in hospitals around the UK, as the best yet, others called it ‘ingenious’ work with ‘tantalising’ results.
And a US doctor hailed it as the best news in his 25-year career.
The revolutionary drug, aducanumab, could stop people from developing Alzheimer’s disease
Alzheimer’s and other forms of dementia affect some 850,000 Britons, with one new case every three minutes.
Existing drugs are of limited benefit and despite billions of pounds being spent on research, no new medicines have hit the market in more than a decade.
While current therapies ease the symptoms, aducanumab tackles the underlying damage in the brain, raising hopes it will be the first to alter the course of the disease.
It contains an antibody that homes in on amyloid, the protein that clogs the brain in Alzheimer's, poisoning and killing the cells.
In preliminary trials, involving 165 people in the early stages of the disease, the Swiss-designed drug triggered the removal of amyloid from the brain.
And in men and women given a monthly infusion of a high dose of the drug, the amyloid all but vanished after a year.
This ‘unprecedented’ effect was deemed so significant that the results have been published in Nature the world’s top science journal.
The new drug has been found to get rid of clumps of the amyloid protein are a hallmark of Alzheimer's and are thought to be harmful to brain cells
US researcher Stephen Salloway, of the Butler Hospital in Rhode Island said: ‘This is the best news I’ve had in my 25 years of doing Alzheimer’s research.
‘It brings new hope to the patients and families most affected by this disease.’
Even more excitingly, the drug seemed to halt the disease.
Men and women who weren’t treated experienced steady declines in memory and day to day functioning, such as the ability to cook for themselves or take out the rubbish but those given high doses of the drug stopped getting any worse after just six months of treatment.
The number of people tested was too small to be sure the drug can really stop the disease in its tracks and a larger trial, involving 2,700 people in the early stage of Alzheimer’s, is underway.
Hospitals and clinics in eight British cities, including London, Newcastle, Glasgow, Edinburgh and Dundee are taking part and are looking for patients.
The trial is due to finish in 2020 and, if aducanumab is deemed safe and effective, it could be available shortly afterwards.
However, there are several hurdles to overcome.
Drugs that have seemed promising when given to small groups of people can fail spectacularly when tested on large numbers.
Plus, aducanumab can cause a worrying side-effect, in which fluid accumulates in the brain, raising the risk of strokes.
Challenges include finding a dose that is high enough to work but not so powerful that it does damage.
Other amyloid-busting antibodies have been tried before.
But aducanumab, which is based on antibodies naturally made by pensioners who seem to be immune to Alzheimer’s, is said to be the best yet.
It is thought it is better at getting into the brain and more likely to zero in on the damaging amyloid than previous drugs.
Read more: http://www.dailymail.co.uk/health/article-3767488/Is-cure-Alzheimer-s-sight-Unprecedented-trial-sees-drug-clear-toxic-proteins-brain.html#ixzz4ROhLwVtk
Follow us: @MailOnline on Twitter | DailyMail on Facebook
No comments:
Post a Comment
Note: only a member of this blog may post a comment.